What is a stock summary page? Click here for an overview.
Business Description
Taysha Gene Therapies Inc
NAICS : 541714
SIC : 2834
ISIN : US8776191061
Share Class Description:
TSHA: Ordinary SharesCompare
Compare
Traded in other countries / regions
TSHA.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2020-09-24Description
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.2 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.88 | |||||
| Debt-to-EBITDA | -0.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.4 | |||||
| Beneish M-Score | -2.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 57.5 | |||||
| 3-Year EPS without NRI Growth Rate | 58.1 | |||||
| 3-Year FCF Growth Rate | 55.4 | |||||
| 3-Year Book Growth Rate | -48 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 73.17 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.61 | |||||
| 9-Day RSI | 31.51 | |||||
| 14-Day RSI | 35.28 | |||||
| 3-1 Month Momentum % | -15.63 | |||||
| 6-1 Month Momentum % | -19.8 | |||||
| 12-1 Month Momentum % | -40.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.42 | |||||
| Quick Ratio | 5.42 | |||||
| Cash Ratio | 5.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -74.6 | |||||
| Shareholder Yield % | -29.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1039.49 | |||||
| Net Margin % | -1071.62 | |||||
| FCF Margin % | -979.23 | |||||
| ROE % | -112.19 | |||||
| ROA % | -51.52 | |||||
| ROIC % | -211.3 | |||||
| 3-Year ROIIC % | -318.18 | |||||
| ROC (Joel Greenblatt) % | -484.78 | |||||
| ROCE % | -63.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 35.98 | |||||
| PB Ratio | 3.6 | |||||
| Price-to-Tangible-Book | 3.6 | |||||
| EV-to-EBIT | -2.18 | |||||
| EV-to-EBITDA | -2.21 | |||||
| EV-to-Revenue | 23.37 | |||||
| EV-to-Forward-Revenue | 76.91 | |||||
| EV-to-FCF | -2.39 | |||||
| Price-to-Net-Current-Asset-Value | 4.85 | |||||
| Price-to-Net-Cash | 5.25 | |||||
| Earnings Yield (Greenblatt) % | -45.87 | |||||
| FCF Yield % | -31.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TSHA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taysha Gene Therapies Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.333 | ||
| EPS (TTM) ($) | -0.36 | ||
| Beta | 0.71 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 125.62 | ||
| 14-Day RSI | 35.28 | ||
| 14-Day ATR ($) | 0.171329 | ||
| 20-Day SMA ($) | 1.68925 | ||
| 12-1 Month Momentum % | -40.44 | ||
| 52-Week Range ($) | 1.17 - 4.32 | ||
| Shares Outstanding (Mil) | 205 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taysha Gene Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taysha Gene Therapies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Taysha Gene Therapies Inc Frequently Asked Questions
What is Taysha Gene Therapies Inc(TSHA)'s stock price today?
The current price of TSHA is $1.27. The 52 week high of TSHA is $4.32 and 52 week low is $1.17.
When is next earnings date of Taysha Gene Therapies Inc(TSHA)?
The next earnings date of Taysha Gene Therapies Inc(TSHA) is 2025-05-14 Est..
Does Taysha Gene Therapies Inc(TSHA) pay dividends? If so, how much?
Taysha Gene Therapies Inc(TSHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers